Fructose and fructose kinase in cancer and other pathologies

Hongfei Jiang; Qian Lin; Leina Ma; Shudi Luo; Xiaoming Jiang; Jing Fang; Zhimin Lu

doi:10.1016/j.jgg.2021.06.006

Fructose and fructose kinase in cancer and other pathologies

J Genet Genomics. 2021 Jul 20;48(7):531-539. doi: 10.1016/j.jgg.2021.06.006. Epub 2021 Jul 7.

Authors

Hongfei Jiang¹, Qian Lin¹, Leina Ma¹, Shudi Luo², Xiaoming Jiang², Jing Fang³, Zhimin Lu⁴

Affiliations

¹ Cancer Institute of The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute, Qingdao 266061, China.
² Zhejiang University Cancer Center, Hangzhou 310029, China.
³ Cancer Institute of The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute, Qingdao 266061, China. Electronic address: jfang@qdu.edu.cn.
⁴ Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China; Zhejiang University Cancer Center, Hangzhou 310029, China. Electronic address: zhiminlu@zju.edu.cn.

PMID: 34326012
DOI: 10.1016/j.jgg.2021.06.006

Abstract

Fructose metabolism and fructose kinase KHK-C/A are key factors in the development of lipid oversynthesis-promoted metabolic disorders and cancer. Here, we summarize and discuss the current knowledge about the specific features of fructose metabolism and the distinct roles of KHK-C and KHK-A in metabolic liver diseases and their relevant metabolic disorders and cancer, and we highlight the specific protein kinase activity of KHK-A in tumor development. In addition, different approaches that have been used to inhibit KHK and the exploration of KHK inhibitors in clinical treatment are introduced.

Keywords: Cancer; Fructose; Glucose; KHK-A; KHK–C; Metabolic disorders; NAFLD; NASH.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Fructose*

Substances

Fructose